Abstracts tagged "biomarkers and scleroderma"

Abstract Number: 799 • 2016 ACR/ARHP Annual Meeting
Biomarker Identification & Molecular Sub-Classification in Systemic Sclerosis for Precision Medicine Using RNA-Seq
Elisha D.O. Roberson^1,2, Li Cao¹, David J. Morales-Heil¹, Benjamin Korman³ and John Varga⁴, ¹Department of Medicine, Washington University, St. Louis, MO, ²Department of Genetics, Washington University, St. Louis, MO, ³Department of Rheumatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁴Rheumatology and Dermatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL
Background/Purpose: Systemic sclerosis (SSc) is a complex and highly heterogeneous disease with multi-organ involvement. Accurate tools for disease sub-classification are lacking. In most patients, skin…
Abstract Number: 1895 • 2016 ACR/ARHP Annual Meeting
Increased CXCL4/PF4 Presence in Systemic Sclerosis and Absence of Heparin Directed Autoantibodies
Boyang Zheng¹, Normand Blais², Jean-Luc Senécal³, Gemma Perez⁴ and Martial Koenig⁵, ¹Division of Internal Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada, ²Hematology, Hôpital Notre-Dame du CHUM, Montreal, QC, Canada, ³Université de Montréal, Montréal, QC, Canada, ⁴Laboratory of autoimmunity, Centre de Recherche du CHUM, Montreal, QC, Canada, ⁵Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada
Background/Purpose: Platelet factor 4 (PF4), also called CXLC4 is a chemokine that is found in higher levels in systemic sclerosis (SSc) patients and is in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].